Reuters logo
BRIEF-Axim Biotechnologies announces phase IIa trial results validating its proprietary cannabinoid delivery method
November 21, 2017 / 2:21 PM / 21 days ago

BRIEF-Axim Biotechnologies announces phase IIa trial results validating its proprietary cannabinoid delivery method

Nov 21 (Reuters) - Axim Biotechnologies Inc:

* Announces phase IIa trial results validating its proprietary cannabinoid delivery method for treatment of irritable bowel syndrome (IBS)

* Study results indicate that CanChew+ was well tolerated by IBS patients and no significant adverse side effects were observed by any participants of trial​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below